Serum Pharmacochemistry Analysis Combined with Network Pharmacology Approach to Investigate the Antiosteoporosis Effect of Xianlinggubao Capsule in vivo

Yun-Hui Xu; Yi-Chun Sun; Jie Liu; Hui-Xin Li; Chun-Yue Huang; Yuan-Yuan Pang; Tong Wu; Xiao Hu

doi:10.1055/s-0041-1726301

Pharmaceutical Fronts, Table of Contents

CC BY 4.0 · Pharmaceutical Fronts 2020; 02(04): e168-e178
DOI: 10.1055/s-0041-1726301

Original Article

Serum Pharmacochemistry Analysis Combined with Network Pharmacology Approach to Investigate the Antiosteoporosis Effect of Xianlinggubao Capsule in vivo

Yun-Hui Xu‡^#

¹State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China

,

Yi-Chun Sun‡^#

²Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China

³Guangdong Efong Pharmaceutical Co., Ltd, Guangzhou, People's Republic of China

,

Jie Liu

¹State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China

,

Hui-Xin Li

²Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China

,

Chun-Yue Huang

¹State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China

,

Yuan-Yuan Pang

²Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China

,

Tong Wu^#

¹State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China

,

Xiao Hu^#

¹State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China

²Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China

› Author Affiliations

Abstract

Xianlinggubao capsule (XLGB) is a traditional Chinese medicine multi-component herbal prescription and has been widely used in osteoporosis (OP) treatment. However, the underlying anti-OP mechanisms of XLGB have not been fully studied. In this study, an ovariectomized rat model of OP was established. The OP rats were orally administrated with XLGB, and then the main absorbed components in serum sample were assessed based on liquid chromatography-tandem mass spectrometry (LC-MS/MS). Subsequently, the potential anti-OP markers in XLGB were screened based on a network pharmacology strategy. Molecular docking analysis was used for confirmation. LC-MS showed 22 absorbed components in the serum sample of OP rat with XLGB treatment. Network pharmacology and pathway analysis suggested 19 potential anti-OP markers in XLGB. According to molecular docking process, most of the potential markers displayed strong interactions with the 22 absorbed components mentioned above. Besides, an absorbed component–potential marker–pathway network was further established. In conclusion, our data suggested the possible mechanisms for XLGB in OP treatment, in which the “multicomponents, multitargets, and multipathways” participated. Our article provided possible direction for drug discovery in OP and could help for exploring novel application of XLGB in clinical setting.

Keywords

xianlinggubao capsule - osteoporosis - mechanism - serum pharmacochemistry analysis - network pharmacology - molecular docking

Full Text

References

References
1 Awasthi H, Mani D, Singh D, Gupta A. The underlying pathophysiology and therapeutic approaches for osteoporosis. Med Res Rev 2018; 38 (06) 2024-2057
2 Madrasi K, Li F, Kim MJ. et al. Regulatory perspectives in pharmacometric models of osteoporosis. J Clin Pharmacol 2018; 58 (05) 572-585
3 Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22 (03) 465-475
4 Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health 2016; 16 (01) 1039
5 Mithal A, Bansal B, Kyer CS, Ebeling P. The Asia-Pacific regional audit-epidemiology, costs, and burden of osteoporosis in India 2013: a report of International Osteoporosis Foundation. Indian J Endocrinol Metab 2014; 18 (04) 449-454
6 Cooper C, Cole ZA, Holroyd CR. et al; IOF CSA Working Group on Fracture Epidemiology. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 2011; 22 (05) 1277-1288
7 Liu K, Tan LJ, Wang P. et al. Functional relevance for associations between osteoporosis and genetic variants. PLoS One 2017; 12 (04) e0174808
8 Liu Y, Liu JP, Xia Y. Chinese herbal medicines for treating osteoporosis. Cochrane Database Syst Rev 2014; 6 (03) CD005467
9 Zhu HM, Qin L, Garnero P. et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. Osteoporos Int 2012; 23 (04) 1317-1327
10 Qin L, Zhang G, Hung WY. et al. Phytoestrogen-rich herb formula “XLGB” prevents OVX-induced deterioration of musculoskeletal tissues at the hip in old rats. J Bone Miner Metab 2005; 23 (Suppl): 55-61
11 State Food and Drug Administration of China, Xianlinggubao Capsule, WS-10269 (ZD-0269)-2002. National Standards Assembly of Chinese Patent Medicine, 2002.
12 Dai Y, Tu FJ, Yao ZH. et al. Rapid identification of chemical constituents in traditional Chinese medicine fufang preparation xianling gubao capsule by LC-linear ion trap/Orbitrap mass spectrometry. Am J Chin Med 2013; 41 (05) 1181-1198
13 Bao H, Guo H, Feng Z, Li X. Deciphering the underlying mechanism of Xianlinggubao capsule against osteoporosis by network pharmacology. BMC Complement Med Ther 2020; 20 (01) 208
14 Lee AY, Park W, Kang TW, Cha MH, Chun JM. Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis. J Ethnopharmacol 2018; 221: 151-159
15 Cheng M, Wang Q, Fan Y. et al. A traditional Chinese herbal preparation, Er-Zhi-Wan, prevent ovariectomy-induced osteoporosis in rats. J Ethnopharmacol 2011; 138 (02) 279-285
16 Bahlous A, Kalai E, Hadj Salah M, Bouzid K, Zerelli L. Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis [in French]. Tunis Med 2006; 84 (11) 751-757
17 Lei T, Liang Z, Li F. et al. Pulsed electromagnetic fields (PEMF) attenuate changes in vertebral bone mass, architecture and strength in ovariectomized mice. Bone 2018; 108: 10-19
18 Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004; 1 (04) 337-341
19 Ru J, Li P, Wang J. et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014; 6: 13
20 Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4 (01) 44-57
21 Lang PT, Brozell SR, Mukherjee S. et al. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 2009; 15 (06) 1219-1230
22 Missiuro PV, Liu K, Zou L. et al. Information flow analysis of interactome networks. PLOS Comput Biol 2009; 5 (04) e1000350
23 Tang Y, Li M, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems 2015; 127: 67-72
24 Geng JL, Dai Y, Yao ZH. et al. Metabolites profile of Xian-Ling-Gu-Bao capsule, a traditional Chinese medicine prescription, in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry analysis. J Pharm Biomed Anal 2014; 96: 90-103
25 Zhang D, Liu L, Jia Z, Yao X, Yang M. Flavonoids of Herba Epimedii stimulate osteogenic differentiation and suppress adipogenic differentiation of primary mesenchymal stem cells via estrogen receptor pathway. Pharm Biol 2016; 54 (06) 954-963
26 Wu Y, Xia L, Zhou Y, Xu Y, Jiang X. Icariin induces osteogenic differentiation of bone mesenchymal stem cells in a MAPK-dependent manner. Cell Prolif 2015; 48 (03) 375-384
27 Zhai YK, Guo XY, Ge BF. et al. Icariin stimulates the osteogenic differentiation of rat bone marrow stromal cells via activating the PI3K-AKT-eNOS-NO-cGMP-PKG. Bone 2014; 66: 189-198
28 You L, Chen L, Pan L, Chen JY. New insights into the gene function of osteoporosis. Front Biosci 2013; 18: 1088-1097
29 Xu F, Ding Y, Guo Y. et al. Anti-osteoporosis effect of Epimedium via an estrogen-like mechanism based on a system-level approach. J Ethnopharmacol 2016; 177: 148-160
30 Higuchi C, Myoui A, Hashimoto N. et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 2002; 17 (10) 1785-1794
31 Peng S, Zhou G, Luk KD. et al. Strontium promotes osteogenic differentiation of mesenchymal stem cells through the Ras/MAPK signaling pathway. Cell Physiol Biochem 2009; 23 (1-3): 165-174
32 David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002; 115 (Pt 22): 4317-4325
33 Ikeda F, Nishimura R, Matsubara T. et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004; 114 (04) 475-484
34 Xi JC, Zang HY, Guo LX. et al. The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis. J Recept Signal Transduct Res 2015; 35 (06) 640-645
35 Ke K, Li Q, Yang X. et al. Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model. Sci Rep 2016; 6: 35233
36 Zhong H, Cao C, Yang J, Huang Q. Research on Relationship of HIF-1 Signaling Pathway and Postmenstrual Osteoporosis [in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban 2017; 48 (06) 862-868
37 Xu Q, Chen G, Liu X, Dai M, Zhang B. Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-κB and MAPK signaling pathways. Biochem Biophys Res Commun 2019; 508 (03) 902-906
38 Amjadi-Moheb F, Akhavan-Niaki H. Wnt signaling pathway in osteoporosis: Epigenetic regulation, interaction with other signaling pathways, and therapeutic promises. J Cell Physiol 2019; 234 (09) 14641-14650

Supplementary Material

Supplementary Material